Evolution of the Average Target: Takeda Pharmaceutical Company Limited

Evolution of the Target Price: Takeda Pharmaceutical Company Limited

Changes in Analyst Recommendations: Takeda Pharmaceutical Company Limited

5c8236cf8dd278ba680a1.VG6W24A4UhK7wRD6eUS-PcWtvq5Got_jCQl8BB9r154.Flfhl8NTCFTU-HucABzZRJbX7NoZ-KasRng3R0wNku4CP_KMxg0TZcOoSQ~998ab457dfe38d0f900bee9ec5eeb656
08-31 Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says MT
07-28 SBI Securities Starts Takeda Pharmaceutical at Neutral with 5,400 Yen Price Target MT
07-24 China Merchants Starts Takeda Pharmaceutical at Buy with 6,600 Yen Price Target MT
03-30 Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says MT
01-30 Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,700 Yen From 5,100 Yen, Keeps at Buy MT
11-11 Neurocrine Biosciences' Depressive Disorder Drug Fails to Meet Primary Goal in Phase 2 Study MT
26/09/25 Alkermes' Stock Dip on Narcolepsy Data Seen as Buying Opportunity, RBC Says MT
20/08/25 Veeva Systems Q2 Results Likely In-Line to Better, Maintain H2 Outlook, Truist Says MT
09/05/25 Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,100 Yen From 5,500 Yen, Keeps at Buy MT
06/05/25 Jefferies Adjusts Takeda Pharmaceutical Company's Price Target to 5,500 Yen From 5,000 Yen, Keeps at Buy MT
12/08/24 Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,000 Yen From 4,800 Yen, Keeps at Buy MT
31/07/24 Jefferies Adjusts Takeda Pharmaceutical's Price Target to 4,800 Yen From 5,600 Yen, Keeps at Buy MT
13/02/24 Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,600 Yen From 5,200 Yen, Keeps at Buy MT
03/10/23 Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,200 Yen From 5,300 Yen, Keeps at Buy MT
22/09/23 Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,300 Yen From 5,100 Yen, Keeps at Buy MT
31/05/23 Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,100 Yen From 5,000 Yen, Keeps at Buy MT
16/05/23 TD Cowen Adjusts Price Target on Takeda Pharmaceutical to $20 From $30, Maintains Outperform Rating MT
04/04/23 TD Cowen Adjusts Price Target on Takeda Pharmaceutical to $30 From $24, Keeps Outperform Rating MT
16/03/23 BofA Securities Upgrades Takeda Pharmaceutical to Buy From Neutral, Price Target $20 MT
06/03/23 Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,000 Yen From 4,600 Yen, Keeps at Buy MT
01/08/22 Jefferies Downgrades Takeda Pharmaceutical to Hold From Buy MT
19/07/22 Cowen Upgrades Takeda Pharmaceutical to Outperform From Market Perform MT
07/10/21 Takeda Pharmaceutical : Morgan Stanley Downgrades Takeda Pharmaceutical to Equal-weight From Overweight MT
09/09/17 Bayer : Germany's Merck hires JP Morgan to sell consumer health RE

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+13.4%
-1%
+6.29%
+3.87%
-5.08%
+29.44%
-12.53%
+2.71%
+4.09%
Average +4.58%
Weighted average by Cap. +5.84%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
5,753.00JPY
Average target price
6,603.31JPY
Spread / Average Target
+14.78%
High Price Target
7,600.00JPY
Spread / Highest target
+32.10%
Low Price Target
5,800.00JPY
Spread / Lowest Target
+0.82%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
-
  1. Stock Market
  2. Stocks
  3. 4502 Stock
  4. TAK Stock
  5. Consensus Takeda Pharmaceutical Company Limited